Table 1.

Baseline characteristics according to randomized left atrial appendage closure

Variable	Not closed (n = 86)	Closed (n = 101)
Age – years	69.3 ± 8.8	67.6 ± 9.6
Men - n (%)	75 (87.2)	84 (83.2)
Clinical characteristics
Congestive heart failure - n (%)	15 (17.9)	16 (15.8)
Atrial fibrillation - n (%)	12 (12.8)	18 (16.8)
Diabetes - n (%)	19 (22.1)	31 (30.7)
Hypertension - n (%)	60 (69.8)	75 (74.3)
CHADS-VASc – unit	2.9 ± 1.4	2.9 ± 1.5
Prior stroke - n (%)	15 (17.4)	11 (10.9)
Chronic kidney diseasea - n (%)	14 (16.3)	15 (14.9)
Medicine
ASA - n (%)	69 (80.2)	75 (74.3)
Clopidogrel - n (%)	14 (16.3)	19 (18.8)
OAC
VKA - n (%)	26 (30.2)	36 (35.6)
NOAC - n (%)	2 (2.2)	2 (2.0)
Beta-blocker - n (%)	47 (54.7)	61 (60.4)
Verapamil - n (%)	4 (4.5)	2 (2.0)
Calcium-blocker - n (%)	19 (21.3)	34 (33.7)
Digoxin - n (%)	5 (5.6)	3 (3.0)
Renin-angiotensin system blocker - n (%)	40 (46.5)	54 (53.5)
Amiodarone - n (%)	23 (26.7)	18 (17.8)
Statin - n (%)	74 (86.0)	81 (80.2)
Procedural characteristics
Surgery type
AVR only - n (%)	17 (19.1)	17 (16.8)
AVR with CABG - n (%)	20 (22.5)	22 (21.8)
AVR with aortic surgery - n (%)	1 (1.1)	1 (1.0)
AVR with MVR - n (%)	0 (0)	2 (2.0)
Aortic surgery only - n (%)	1 (1.1)	0 (0)
CABG only - n (%)	40 (46.5)	50 (49.5)
CABG with MVR - n (%)	2 (2.3)	2 (2.0)
MVR only - n (%)	4 (4.5)	7 (6.9)
Tricuspid surgery only - n (%)	1 (1.2)	0 (0)
Perioperative atrial fibrillation - n (%)	52 (60.5)	50 (50.0)

Abbreviations CHADS-VASc Congestive heart failure, hypertension, age [≥75 years], diabetes, stroke – peripheral vascular disease, age [≥65 years], sex-category, OAC Oral anticoagulation, VKA Vitamin K-antagonist, NOAC Novel oral anticoagulation, IQR: interquartile range

^aeGFR< 30 ml/min